Dr. He on the Results of the LEGACY Study Examining Y-90 in HCC
Ruth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.
Dr. He on Future Treatment for Patients With Hepatocellular Carcinoma
Aiwu Ruth He, MD, discusses the combination regimen of bevacizumab and atezolizumab in patients with advanced-stage hepatocellular carcinoma.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512